Alverix Working with BD to Develop and Manufacture Next-Generation POC Systems

BD Selects Alverix to Develop Instrumentation to Be Part of New System to Improve Infectious Disease Diagnoses at Point-of-Care

SAN JOSE, Calif.--(BUSINESS WIRE)-- As consumers begin to take greater ownership of their own healthcare, there is a growing demand for accessibility to diagnostic testing. Alverix, Inc. and BD (Becton, Dickinson and Company) are on the cutting edge of this trend and today announced an agreement to produce assay systems at the point-of-care (POC) that will improve infectious disease diagnoses.

When combined with existing diagnostic tests, or with assays currently being developed, Alverix’s devices enable central laboratory quality results to be realized in any location where rapid test information is critical to patient care. Until now, this level of performance required expensive, bench-top instrumentation. In contrast, Alverix’s detection devices provide immediate, accurate results at POC – in doctors’ offices – for a fraction of the cost and turn around time of traditional methods.

“The cost and efficiency of critical diagnoses will be greatly augmented as more diagnostic tests are performed more quickly at the point of care,” said Ric Tarbox, CEO of Alverix. “Our technology has the potential to revolutionize medical diagnostics and dramatically improve patient care by enabling more sensitive, affordable, immediate and accurate testing for acute and chronic health conditions, in all near- patient settings. By working with BD, we are able to help expand the accessibility of existing and new assays and promote the next generation of diagnostics that will be designed for broad use by healthcare professionals and patients.”

“Alverix’s technology delivers greater sensitivity and accuracy at a greatly reduced cost to traditional bench-top instruments,” said Greg Miziolek, VP, BD Diagnostics, Point of Care. “In line with BD’s purpose of ‘Helping all people live healthy lives,’ the Company strives to improve the speed and accuracy of infectious disease diagnosis. We seek to introduce faster, more accurate tests that have the potential to enable physicians to initiate appropriate treatment sooner, speed the diagnosis of infectious diseases, and improve patient outcomes.”

About Alverix

Alverix is a leader in providing next-generation instrument and connectivity platforms for diagnostic Point-of-Care (POC) testing. Building upon a 30-year legacy within Hewlett Packard and Agilent, Alverix was spun off as a privately held company in 2007 and is based in San Jose, CA. Alverix’s systems enable laboratory class performance in a mobile, inexpensive format, extending testing beyond high volume sites to physician office labs, retail clinics, emerging markets and the home. Alverix’s target markets include infectious disease, drugs of abuse (DOA), cardiac markers, cholesterol/lipids, glucose and hemoglobin, among others. With strength in product design, product development and high volume manufacturing, Alverix is leading the transition of diagnostic testing from the laboratory to all locations where immediate results are critical to patient care.


for Alverix, Inc.
Theresa Murray, 610-642-8253 x164
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Technology  Data Management  Software  Health  Hospitals  Medical Devices